Q: What is Hemgenix used for?

Hemgenix is used to treat hemophilia B .

Q: How does Hemgenix work?

Mechanism of Action Hemophilia B is caused by a mutation in the gene responsible for producing Factor IX, a protein necessary for blood to clot. Hemgenix uses gene therapy technology to address this deficiency directly. The treatment consists of a modified, harmless virus known as a viral vector. This vector acts as a delivery system to transport a working copy of the Factor IX gene into the liver cells. The virus itself does not cause disease and cannot replicate inside the body. Once the functional gene reaches the liver, the following occurs: Protein Synthesis: The liver cells begin using the new genetic instructions to manufacture the Factor IX protein. Bloodstream Integration: The newly produced Factor IX is released into the blood, where it helps the body form clots normally. Bleeding Prevention: With higher levels of Factor IX circulating in the body, patients experience fewer bleeding episodes and a reduced need for frequent protein replacement injections. This approach is intended as a one-time infusion. By providing the liver with a permanent set of instructions to create the missing protein, the therapy aims to provide long-term protection against bleeding complications associated with Hemophilia B.

Q: What are the active ingredients in Hemgenix?

The active ingredient in Hemgenix is etranacogene dezaparvovec .

Q: What are the side effects of Hemgenix?

Common side effects of Hemgenix may include: Elevated liver enzymes Headache Fatigue Always consult with a healthcare professional about potential side effects.

Q: What is the dosage of Hemgenix and how do I take it?

How Hemgenix is Given Hemgenix is administered as a single-dose intravenous (IV) infusion. It is not a medication you take at home; instead, it is given by a healthcare professional in a hospital or specialized infusion center. The infusion process typically takes about one to two hours to complete. Preparation Before you receive the treatment, your doctor will perform blood tests to check your liver health and to ensure you do not have certain antibodies that could interfere with the medication. Your healthcare provider may also give you other medications shortly before the infusion starts to help prevent potential infusion reactions. Follow-Up and Monitoring Because Hemgenix is a one-time treatment, there are no daily doses to manage. However, you will need to have regular blood tests for an extended period after the infusion. These tests allow your medical team to monitor your liver function and measure the levels of factor IX in your blood to determine how well the treatment is working.

Q: Is Hemgenix safe during pregnancy and breastfeeding?

Pregnancy Hemgenix is a gene therapy indicated for the treatment of adults with Hemophilia B. Because Hemophilia B primarily affects males and the medication is approved for use in adult males, there is no information available regarding its use in pregnant women. No animal reproductive studies have been conducted with this medication to evaluate potential risks to a fetus. Breastfeeding It is not known whether Hemgenix is present in human milk or if it has any effects on a breastfed infant or milk production. Because the medication is intended for use in adult males, data regarding its safety during lactation are not available. Patients should discuss any questions regarding reproductive health or the use of gene therapy with their healthcare provider.

Q: What forms and strengths does Hemgenix come in?

Dosage Forms Hemgenix is available as a suspension for intravenous infusion. It is a sterile, clear to slightly opalescent, and colorless liquid. Strengths and Packaging The medication is supplied in single-dose vials. Because the total dose is calculated based on the patient's body weight, Hemgenix is distributed in kits that contain a specific number of vials. These kits may include: Between 10 and 48 vials per kit. Each vial contains a standardized concentration of the active ingredient, etranacogene dezaparvovec-drlb. The healthcare provider determines the exact number of vials needed for a single one-time infusion based on the patient's weight in kilograms.

Q: What is the FDA approval status of Hemgenix?

FDA Approval Status The U.S. Food and Drug Administration (FDA) approved Hemgenix in November 2022. It is classified as an adeno-associated virus vector-based gene therapy and was the first gene therapy approved for the treatment of Hemophilia B. Approved Indications Hemgenix is approved for use in adults with Hemophilia B (congenital Factor IX deficiency). It is specifically indicated for patients who meet at least one of the following criteria: They currently use Factor IX prophylaxis therapy. They have a current or historical life-threatening hemorrhage. They experience repeated, serious spontaneous bleeding episodes. Safety and Monitoring The FDA has not issued a boxed warning for Hemgenix. Regulatory labeling requires healthcare providers to monitor patients for adverse reactions during the infusion and to perform regular blood tests to check liver enzyme levels for several months following treatment to monitor for potential liver injury.

Question 1

What is Hemgenix?

Accepted Answer

Hemgenix is a gene therapy designed to address a deficiency in clotting Factor IX. It uses a viral vector to deliver a functional gene into the liver cells.

Once the gene is delivered, the liver can begin producing the Factor IX protein. This process is intended to increase the levels of clotting factor circulating in the blood, which helps the blood to clot more effectively.

Question 2

What is Hemgenix used for?

Accepted Answer

Hemgenix is used to treat hemophilia B.

Question 3

How does Hemgenix work?

Accepted Answer

Mechanism of Action

Hemophilia B is caused by a mutation in the gene responsible for producing Factor IX, a protein necessary for blood to clot. Hemgenix uses gene therapy technology to address this deficiency directly.

The treatment consists of a modified, harmless virus known as a viral vector. This vector acts as a delivery system to transport a working copy of the Factor IX gene into the liver cells. The virus itself does not cause disease and cannot replicate inside the body.

Once the functional gene reaches the liver, the following occurs:

Protein Synthesis: The liver cells begin using the new genetic instructions to manufacture the Factor IX protein.
Bloodstream Integration: The newly produced Factor IX is released into the blood, where it helps the body form clots normally.
Bleeding Prevention: With higher levels of Factor IX circulating in the body, patients experience fewer bleeding episodes and a reduced need for frequent protein replacement injections.

This approach is intended as a one-time infusion. By providing the liver with a permanent set of instructions to create the missing protein, the therapy aims to provide long-term protection against bleeding complications associated with Hemophilia B.

Question 4

What are the active ingredients in Hemgenix?

Accepted Answer

The active ingredient in Hemgenix is etranacogene dezaparvovec.

Question 5

What are the side effects of Hemgenix?

Accepted Answer

Common side effects of Hemgenix may include:

Elevated liver enzymes
Headache
Fatigue

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Hemgenix?

Accepted Answer

Hemgenix belongs to the gene therapy for hemophilia B drug class.

Question 7

What is the dosage of Hemgenix and how do I take it?

Accepted Answer

How Hemgenix is Given

Hemgenix is administered as a single-dose intravenous (IV) infusion. It is not a medication you take at home; instead, it is given by a healthcare professional in a hospital or specialized infusion center. The infusion process typically takes about one to two hours to complete.

Preparation

Before you receive the treatment, your doctor will perform blood tests to check your liver health and to ensure you do not have certain antibodies that could interfere with the medication. Your healthcare provider may also give you other medications shortly before the infusion starts to help prevent potential infusion reactions.

Follow-Up and Monitoring

Because Hemgenix is a one-time treatment, there are no daily doses to manage. However, you will need to have regular blood tests for an extended period after the infusion. These tests allow your medical team to monitor your liver function and measure the levels of factor IX in your blood to determine how well the treatment is working.

Question 8

Is Hemgenix safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Hemgenix is a gene therapy indicated for the treatment of adults with Hemophilia B. Because Hemophilia B primarily affects males and the medication is approved for use in adult males, there is no information available regarding its use in pregnant women. No animal reproductive studies have been conducted with this medication to evaluate potential risks to a fetus.

Breastfeeding

It is not known whether Hemgenix is present in human milk or if it has any effects on a breastfed infant or milk production. Because the medication is intended for use in adult males, data regarding its safety during lactation are not available.

Patients should discuss any questions regarding reproductive health or the use of gene therapy with their healthcare provider.

Question 9

What forms and strengths does Hemgenix come in?

Accepted Answer

Dosage Forms

Hemgenix is available as a suspension for intravenous infusion. It is a sterile, clear to slightly opalescent, and colorless liquid.

Strengths and Packaging

The medication is supplied in single-dose vials. Because the total dose is calculated based on the patient's body weight, Hemgenix is distributed in kits that contain a specific number of vials. These kits may include:

Between 10 and 48 vials per kit.

Each vial contains a standardized concentration of the active ingredient, etranacogene dezaparvovec-drlb. The healthcare provider determines the exact number of vials needed for a single one-time infusion based on the patient's weight in kilograms.

Question 10

What is the FDA approval status of Hemgenix?

Accepted Answer

FDA Approval Status

The U.S. Food and Drug Administration (FDA) approved Hemgenix in November 2022. It is classified as an adeno-associated virus vector-based gene therapy and was the first gene therapy approved for the treatment of Hemophilia B.

Approved Indications

Hemgenix is approved for use in adults with Hemophilia B (congenital Factor IX deficiency). It is specifically indicated for patients who meet at least one of the following criteria:

They currently use Factor IX prophylaxis therapy.
They have a current or historical life-threatening hemorrhage.
They experience repeated, serious spontaneous bleeding episodes.

Safety and Monitoring

The FDA has not issued a boxed warning for Hemgenix. Regulatory labeling requires healthcare providers to monitor patients for adverse reactions during the infusion and to perform regular blood tests to check liver enzyme levels for several months following treatment to monitor for potential liver injury.

Question 11

What should I know about Hemgenix and cost?

Accepted Answer

Treatment Cost

The list price for Hemgenix is approximately $3.5 million per dose. It is administered as a single, one-time intravenous infusion. While the initial cost is high, the treatment is designed to provide long-term production of Factor IX, which may reduce or eliminate the need for ongoing prophylactic infusions that are traditionally required for hemophilia B management.

Insurance and Financial Assistance

The actual out-of-pocket cost to a patient depends on several factors, including:

Insurance Coverage: Most private and public health insurance plans require a detailed prior authorization process before approving coverage for gene therapy.
Negotiated Rates: The final cost paid by insurers often differs from the list price due to negotiated discounts or value-based payment arrangements.
Patient Support Programs: The manufacturer may offer financial assistance or navigation services to help eligible patients understand their coverage and manage costs.

Patients are encouraged to work closely with their healthcare provider and insurance company to determine specific coverage details and any potential financial responsibilities before starting treatment.

Hemgenix

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Hemgenix

Hospitals.net Disclosure